For decades researchers have tried and failed to develop an effective obesity treatment. The current range of options includes drugs with side effects or surgery. That could be set to change with a new study published in the New England Journal of Medicine offering hope to millions. The study saw 2,000 participants across 16 countries inject themselves with the Type 2 diabetes drug semaglutide for 68 weeks. The appetite suppressing drug delivered a 15% decrease in body fat on average, while those who received a placebo shed 2.4%. And unlike other obesity medications on the market, semaglutide has little to no side effects. The study’s lead researcher Dr Robert Kushner called the drug a “game-changer”.